research Polyherbal chocolate supplementation - a novel adjuvant therapy for polycystic ovary syndrome (PCOS)
Polyherbal chocolate may help manage PCOS symptoms.
Search
for
Sort by
Research
510-540 / 1000+ results
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research ACOG Practice Bulletin No. 108: Polycystic Ovary Syndrome
The bulletin provides guidelines for diagnosing and managing PCOS, suggesting weight loss, hormonal contraceptives, and diabetes screening, with clomiphene for infertility and various treatments for excess hair.
research Hormonal Therapies for Acne: A Comprehensive Update for Dermatologists
Hormonal therapies effectively treat acne and improve quality of life.
research Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases
Sacituzumab Tirumotecan shows promise in treating gynecologic cancers with manageable side effects.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research Determination of Exemestane in Human Plasma by LC-MS-MS
The method effectively showed that the two exemestane preparations are bioequivalent.
research LB822 Nutraceuticals known to promote hair growth do not interfere with the inhibitory action of tamoxifen in breast cancer cells
Hair growth supplements do not reduce the effectiveness of the breast cancer treatment tamoxifen.
research Journal of Population Therapeutics and Clinical Pharmacology
Baricitinib is more effective than methotrexate for severe alopecia areata.
research Managing the PCOS-Related Symptoms of Hirsutism, Acne, and Hair Loss
Birth control pills and anti-androgen medications help manage hair growth, acne, and hair loss in women with PCOS.
research 193 Unveiling the role of estradiol in the pathogenesis of female pattern hair loss
research Imiquimod for Cervical and Vaginal Intraepithelial Neoplasia
Imiquimod may be a better non-surgical treatment for cervical pre-cancer, but its effectiveness for vaginal pre-cancer is unclear, and it has some side effects.
research A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
research Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Broad Ligament Maneuver Reverses All Signs and Symptoms of PCOS – Case Study
The Broad Ligament Maneuver effectively relieved PCOS symptoms and restored ovarian function.
research Compatibility of 17-α-Estradiol, Betamethasone, Finasteride, Melatonin, Prednicarbate, and Spironolactone in TrichoFoam™ - a Foaming Vehicle for Personalized Alopecia Treatments.
TrichoFoam™ effectively delivers multiple hair loss treatments, maintaining their stability and effectiveness.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Compatibility of Caffeine Clobetasol Propionate Dutasteride Nicotinamide and Progesterone in TrichoFoam™, a Natural Vehicle for Hair Foams.
TrichoFoam™ is a stable option for personalized hair loss treatment with most ingredients remaining effective for 90-180 days.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Effects of supplementation with two probiotic strains (Lactobacillus helveticus and Bifidobacterium longum) on hormonal status, oxidative stress, and clinical symptoms in women with polycystic ovary syndrome: a randomized clinical trial
Probiotic supplements may help reduce inflammation and oxidative stress in women with PCOS.
research Del "contexto expandido" a la mesa de negociación
Curcumin improves blood sugar and cholesterol in PCOS patients.
research The comparison of treatment with clobetasol propionate 0.05% and topical pimecrolimus 1% treatment in the treatment of alopecia areata
Clobetasol and pimecrolimus are similarly effective for alopecia areata, but pimecrolimus has fewer side effects and is preferred for long-term use.
research The effects of pro-, pre- and synbiotics supplementation on polycystic ovary syndrome: an umbrella review of meta-analyses of randomized controlled trials
Probiotics and synbiotics may help with PCOS symptoms, but more research is needed.
research Hirsutism and acne in polycystic ovary syndrome
Lower doses of treatments for hirsutism and acne in PCOS are effective and cause fewer side effects.
research The evolution of primary multimodality treatment in resectable breast cancer
Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.
research ВЫБОР ТЕРАПИИ У ПАЦИЕНТОК С СИНДРОМОМ ПОЛИКИСТОЗНЫХ ЯИЧНИКОВ В ПОЗДНЕМ РЕПРОДУКТИВНОМ ВОЗРАСТЕ
Combined oral contraceptives and antiandrogens are effective for treating PCOS symptoms in older women.
research Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Experimental Assessment of 3-meta-Pyridine-1,2,4-Oxadiazole Deoxycholic Acid Derivative as a Prototype of 5-α-Reductase Inhibitors in silico and in vivo Models
The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.